Bhatnagar A, Parvathareddy V, Winkelmayer W, Chertow G, Erickson K
Med Care. 2023; 61(11):787-795.
PMID: 37721983
PMC: 10592119.
DOI: 10.1097/MLR.0000000000001924.
Zhang F, Zhang T, Yang S, Wang D, Zhuo Q, Qin X
Front Med (Lausanne). 2022; 9:831541.
PMID: 35721096
PMC: 9203730.
DOI: 10.3389/fmed.2022.831541.
Prasad B, Jafari M, Toppings J, Gross L, Kappel J, Au F
Can J Kidney Health Dis. 2020; 7:2054358120927532.
PMID: 32547774
PMC: 7273547.
DOI: 10.1177/2054358120927532.
Aapro M, Gascon P, Patel K, Rodgers G, Fung S, Arantes Jr L
Front Pharmacol. 2019; 9:1498.
PMID: 30687083
PMC: 6333861.
DOI: 10.3389/fphar.2018.01498.
Park H, Liu X, Henry L, Harman J, Ross E
BMC Nephrol. 2018; 19(1):318.
PMID: 30413150
PMC: 6230235.
DOI: 10.1186/s12882-018-1119-7.
Perspective: Will We Ever Know the Optimal Hgb Level in ESRD?.
Wish J
J Am Soc Nephrol. 2018; 29(10):2454-2457.
PMID: 30185470
PMC: 6171266.
DOI: 10.1681/ASN.2018040363.
Medical safety in the care of the person with end-stage kidney disease.
Duronville J, Diamantidis C
Semin Dial. 2018; 31(2):140-148.
PMID: 29315834
PMC: 5839985.
DOI: 10.1111/sdi.12672.
Iron Overload in Dialysis Patients: Rust or Bust?.
Coyne D
Kidney Int Rep. 2017; 2(6):995-997.
PMID: 29270510
PMC: 5733671.
DOI: 10.1016/j.ekir.2017.08.014.
The relationship between dialysis adequacy and serum uric acid in dialysis patients; a cross-sectional multi-center study in Iranian hemodialysis centers.
Nemati E, Khosravi A, Einollahi B, Meshkati M, Taghipour M, Abbaszadeh S
J Renal Inj Prev. 2017; 6(2):142-147.
PMID: 28497092
PMC: 5423283.
DOI: 10.15171/jrip.2017.28.
Conservative Management of Chronic Renal Failure.
Narula A, Hooda A
Med J Armed Forces India. 2016; 63(1):56-61.
PMID: 27407940
PMC: 4921719.
DOI: 10.1016/S0377-1237(07)80112-2.
Prevalence, awareness, and treatment of anemia in Chinese patients with nondialysis chronic kidney disease: First multicenter, cross-sectional study.
Li Y, Shi H, Wang W, Peng A, Jiang G, Zhang J
Medicine (Baltimore). 2016; 95(24):e3872.
PMID: 27310973
PMC: 4998459.
DOI: 10.1097/MD.0000000000003872.
Erythropoiesis-stimulating Agents and Anemia in Patients with Non-dialytic Chronic Kidney Disease.
Kim S, Kim K, Kwon S, Kim H
J Korean Med Sci. 2016; 31(1):55-60.
PMID: 26770038
PMC: 4712580.
DOI: 10.3346/jkms.2016.31.1.55.
Association of Erythropoietin Dose and Route of Administration with Clinical Outcomes for Patients on Hemodialysis in the United States.
Wright D, Wright E, Narva A, Noguchi C, Eggers P
Clin J Am Soc Nephrol. 2015; 10(10):1822-30.
PMID: 26358266
PMC: 4594062.
DOI: 10.2215/CJN.01590215.
Considerations and challenges in defining optimal iron utilization in hemodialysis.
Charytan D, Pai A, Chan C, Coyne D, Hung A, Kovesdy C
J Am Soc Nephrol. 2014; 26(6):1238-47.
PMID: 25542967
PMC: 4446883.
DOI: 10.1681/ASN.2014090922.
Optimal hematocrit based on regional cerebral blood flow in hemodialysis patients with diabetic nephropathy.
Oh T, Sakayori O, Kamano C, Komaba Y, Iino Y, Katayama Y
Clin Exp Nephrol. 2014; 6(3):140-6.
PMID: 24989953
DOI: 10.1007/BF03353390.
Unit dosing of darbepoetin alfa for thetreatment of anemia in patients with end-stage renal disease being switched from recombinant human erythropoietin: Results of a phase IIIb, 27-week, multicenter, open-label study in Greek patients.
Bristoyiannis G, Germanos N, Grekas D, Hatzidimitriou C, Iatrou C, Memmos D
Curr Ther Res Clin Exp. 2014; 66(3):195-211.
PMID: 24672123
PMC: 3964579.
DOI: 10.1016/j.curtheres.2005.06.009.
Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010).
Winkelmayer W, Mitani A, Goldstein B, Brookhart M, Chertow G
JAMA Intern Med. 2014; 174(5):699-707.
PMID: 24589911
PMC: 4286316.
DOI: 10.1001/jamainternmed.2014.87.
Stable hemoglobin in hemodialysis patients: forest for the trees--a 12-week pilot observational study.
Rottembourg J, Kpade F, Tebibel F, Dansaert A, Chenuc G
BMC Nephrol. 2013; 14:243.
PMID: 24180578
PMC: 4228386.
DOI: 10.1186/1471-2369-14-243.
Why multidisciplinary clinics should be the standard for treating chronic kidney disease.
Filler G, Lipshultz S
Pediatr Nephrol. 2012; 27(10):1831-4.
PMID: 22760413
DOI: 10.1007/s00467-012-2236-3.
The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial.
Coyne D
Kidney Int. 2012; 82(2):235-41.
PMID: 22437411
PMC: 3388517.
DOI: 10.1038/ki.2012.76.
